Ser211

Site Information
EStSLGDsDEEDTMS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 14159828

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 4 , 5 , 6 , 7 )
Disease tissue studied:	HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , cervical cancer ( 5 ) , cervical adenocarcinoma ( 5 ) , leukemia ( 7 ) , chronic myelogenous leukemia ( 7 )
Relevant cell line - cell type - tissue:	breast ( 2 ) , HeLa (cervical) ( 4 ) , HeLa S3 (cervical) ( 5 ) , Jurkat (T lymphocyte) ( 6 ) , K562 (erythroid) ( 7 )

References
1	Nielsen CP, et al. (2019) USP9X Deubiquitylates DVL2 to Regulate WNT Pathway Specification. Cell Rep 28, 1074-1089.e5 31340145 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
5	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
6	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
7	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info